FRSPF

Executive Summary

Integrated LFP Phosphate Play at an Inflection Point

First Phosphate (FRSPF / Nasdaq: PHOS) is a pre-revenue Quebec developer positioning its Bégin-Lamarche igneous phosphate deposit as the anchor of a fully integrated North American LFP battery supply chain. The Dec-2024 PEA showed after-tax NPV8 of C$1.59B and 33% IRR against C$675M initial capex, on 900,000 tpa of 40% P2O5 concentrate over a 23-year life. A 2026 resource update lifted indicated resources 378% to 198.5 Mt @ 6.0% P2O5. Validation is stacking up: definitive offtakes for 200,000 tpa concentrate and 60,000 tpa phosphoric acid, US$170M EXIM and up to C$275M EIFO letters of interest, G7 Critical Minerals Alliance selection, a US DoD 'Met' rating, and an Aug-2026 Nasdaq uplisting. But the stock is up 438% off its 52-week low with RSI near 70, and the true share count is ~190M — implying a market cap near US$305M, far above the stale ~$120M EDGAR-derived figure — financing, permitting and feasibility execution to 2029 first production remain the gating risks.

Project & Market Vitals

PEA economics vs a re-rated share price — Sourced project figures alongside verified trading data — note the share count is materially higher than the stale EDGAR cover (73.79M as of Jul 2024 vs ~189M actual)

Price (FRSPF)

$1.62

OTCQX, 2026-08-19 · CSE: PHOS · Nasdaq ADR: PHOS (10:1)

52-Week Range

$0.30–$1.83

+438% off the low, −11.3% from the high

RSI (14)

69.7

At the overbought threshold; 50-DMA $1.18, 200-DMA $0.89

Market Cap

~$120M*

*Stale 73.79M-share EDGAR cover; verified ~189M shares implies ~$305M — use the larger figure for valuation

PEA NPV8 (after-tax)

C$1.59B

33% IRR, 2.6-yr payback, 23-yr life (Dec-2024 PEA; ±30–50% accuracy)

Initial Capex

C$675M

US$170M EXIM LOI + up to C$275M EIFO guarantee LOI + Italian ECA LOIs against it — all non-binding

Indicated Resource

198.5 Mt @ 6.0%

P2O5, +378% vs 2024 MRE; rare high-purity igneous anorthosite host; 40.4% concentrate at 88% recovery

Cash Position

C$30M+

Post July 2026 C$17.7M raise · debt-free · ~C$21.5M non-repayable federal contributions

Mine-to-Battery Vertical

From rare igneous phosphate to North American LFP cathode supply

C$1.59B / 33%

PEA After-Tax NPV8 / IRR

Dec-2024 PEA: pre-tax C$2.1B NPV8, 37.1% IRR; C$675M initial capex; 2.6-yr payback; 23-yr mine life

198.5 Mt @ 6.0%

Indicated Resource (P2O5)

+378% vs 2024 initial MRE; plus 89.5 Mt inferred @ 6.16%; met tests hit 40.4% P2O5 concentrate at 88% recovery

200,000 tpa

Definitive Concentrate Offtake

Signed Jan 5, 2026, plus 60,000 tpa phosphoric acid offtake (Dec 2024); backed by US$170M EXIM LOI and up to C$275M EIFO guarantee LOI

Dec 2024

Positive PEA at Bégin-Lamarche

After-tax NPV8 C$1.59B, 33% IRR, C$675M capex, 900,000 tpa of 40% P2O5 concentrate over 23 years; technical report filed Jan 2025.

H1 2026

Resource +378%, offtakes and G7 backing

Indicated MRE grows to 198.5 Mt @ 6.0% P2O5; definitive 200,000 tpa concentrate offtake (Jan 5); EIFO LOI up to C$275M (Mar 30); Italian SACE/CDP/SIMEST/MAIRE LOIs for the Port Saguenay acid plant; named to Canada's 13-project G7 Critical Minerals Alliance list.

Aug 2026

Nasdaq Global Market uplisting

ADRs uplist under ticker PHOS effective Aug 10, 2026 (10 shares/ADR, no new equity issued); company reports C$30M+ cash and ~C$21.5M in non-repayable Government of Canada contributions.

Late 2026 – 2027

Feasibility study, BAPE and FID

Management targets a full feasibility study by end-2026/early-2027 (skipping PFS), Quebec BAPE permitting through 2027, and FID by end-2027; project financing via EXIM/EIFO/Italian ECAs is the critical path.

2029E

Targeted first production

If permits and financing land on schedule, first concentrate production targeted for 2029, feeding the planned Port Saguenay phosphoric acid plant and downstream LFP CAM ambitions with Prayon, American Battery Factory and Ultion.

Earnings & Signals

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

FY+1 EPS ConsensusN/A — pre-revenue; no published forward EPS estimates

FY+2 EPS ConsensusN/A — pre-revenue

PEG RatioN/A — no earnings or growth estimates

Forward P/EN/A — negative earnings, no revenue

EPS Revisions (90d)↑0 ↓0 (Flat — the only named covering firm held Buy/C$4.94 unchanged June–August 2026; no sell-side EPS estimates exist to revise)

Guidance AccuracyNo earnings guidance (development-stage). Actual burn: net loss C$7.99M for the quarter ended May 31, 2026 (vs C$1.75M a year earlier); TTM net loss ≈ C$29.7M, ≈ −C$0.22/sh on ~189M shares. Debt-free; ~C$80M raised since June 2022 across management-led placements; ~C$21.5M in non-repayable federal contributions.

Earnings Surprise Track Record

Q1 FY2027 (3 mo ended May 31, 2026) Est: n/a Act: net loss C$7.99M (≈ −C$0.04/sh on ~189M shares) —

FY2026 (12 mo ended Feb 28, 2026) Est: n/a Act: TTM net loss ≈ C$29.7M, ≈ −C$0.22/sh —

Beat RateN/A — no sell-side estimates exist for this pre-revenue developer

Insider Activity (90 Days)

Net Buying/Selling+420,000 shares net to CEO (RSU vesting, Jul 3, 2026); no insider open-market sales located in the trailing 90 days

Sell/Buy Ratio~0.0 — no disclosed sales found; acquisitions only (insiders also participated in the management-led June/July placement)

Constructive. Canadian issuer — insider filings live on SEDI, not US Form 4s, so this is assembled from early-warning releases and aggregator data rather than a complete SEDI pull. Within that limit: the CEO's drop below 10% came from dilution, not disposition, and he has been a serial open-market buyer (~2.87M shares since May 2023).

All remaining warrants/options/RSUs are insider-held per the May 4, 2026 capitalization release — alignment is good, but future exercises accrue to insiders at legacy strikes (e.g., C$1.25 warrants exercised April 2026 for C$3.07M).

Peer Comparison

Relative Valuation vs. Competitors

Company	P/E (fwd)	EV/Rev	Rev Growth	Gross Margin
First Phosphate	n/a (pre-revenue)	P/NAV ~0.26x on ~190M sh	First prod. targeted 2029E	PEA after-tax IRR 33%
Arianne Phosphate	n/a (pre-revenue)	P/NAV ~0.03x (pre-tax)	FS-stage, unfinanced	FS NPV8 US$1.91B / IRR 20.7%
Nutrien	~13.4x (current P/E)	n/a (rev $26.9B TTM)	Mature fertilizer major	Net margin 8.9%
Mosaic	n/m (Q2'26 net loss)	n/a (Q2'26 rev $2.8B)	Cyclical, under pressure	$273M Q2'26 net loss

Conventional multiples are meaningless for pre-revenue developers, so NAV framing is substituted. First Phosphate trades at roughly 0.26x its C$1.59B after-tax PEA NPV8 on the verified ~190M share count (~US$305M implied cap) — a premium to fellow Saguenay developer Arianne Phosphate near 0.03x its (pre-tax) feasibility-stage NPV despite Arianne being technically further along. The gap is the battery-grade purity story, definitive offtakes, ECA financing LOIs and the Nasdaq listing versus Arianne's stalled fertilizer-market financing. Nutrien and Mosaic are profitable fertilizer-major context only — First Phosphate's end market is LFP batteries, not fertilizer.

Valuation

Price Targets & Scenarios

Scenario	Price Target	Assumptions	Probability
Feasibility Confirms, ECAs Firm Up, Institutions Arrive	$2.60	The feasibility study lands on schedule with economics at or above PEA, BAPE proceeds without major delay, EXIM/EIFO letters of interest convert toward commitments, and the Nasdaq listing draws first institutional ownership. Risked P/NAV re-rates from ~0.26x toward ~0.45x on the after-tax NPV even with modest dilution.	30%
On Track, But Dilution and Capex Creep	$1.75	Feasibility is delivered end-2026/early-2027 with the sector-typical capex uplift; permitting advances into BAPE; another equity raise (~10% dilution) funds the year. Risked P/NAV holds around ~0.30x across ~210M shares — the stock digests its +438% run rather than extending it.	45%
Slippage + China Price War + Momentum Unwind	$0.90	Feasibility or BAPE slips 12+ months, Chinese LFP/PPA overcapacity reignites below-cost pricing and undermines the ex-China premium thesis, and the Q4 2026 placement-stock unlock hits a thin tape. Price retraces to the 200-DMA zone where the warrant-exercise cost base sits.	25%

Probability-Weighted Target: $1.80 (+11% vs current $1.62)

$1.80

Weighted

Bull $2.6030%

Base $1.7545%

Bear $0.9025%

Analyst Consensus

Emerging Growth Research

C$4.94

Buy reiterated Aug 17, 2026 post-uplisting (sum-of-the-parts; sponsored small-cap research — weight accordingly)

Unnamed firm (TipRanks)

C$1.59

Street-low Buy — the conservative anchor among the 3 covering analysts

Unnamed firm (TipRanks)

~C$2.26

Implied third target backing the C$2.93 average; firm not publicly disclosed

Red Cloud / Haywood / Beacon

—

No published bank or boutique coverage found — EGR is the only named shop; consensus is thin

3 Buy · 0 Hold · 0 Sell — TipRanks/StockAnalysis show 'Strong Buy' from 3 analysts — all Buy — averaging C$2.93 (high C$4.94 / low C$1.59), ~30% above the CSE price. Coverage is thin and includes paid/sponsored research, so the consensus deserves a haircut.

Technical

Key Levels & Options Intelligence

S/RSupport & Resistance

52w High — post-uplisting spike, key resistance

$1.83

Current — RSI 69.7, extended

$1.62

Placement pricing (C$2.00 units, Jun–Jul 2026) — first support

~$1.45

50-DMA — primary uptrend support

$1.18

Warrant strike zone (C$1.25, exercised Apr 2026)

~$0.91

200-DMA — bull/bear line

$0.89

52w Low

$0.30

OptOptions & Sentiment

US options chain: None — PHOS ADR listed on Nasdaq only since Aug 10, 2026; no listed options yet
Short interest: Not yet reported for the Nasdaq ADR; pre-uplist OTC data showed ~3.6 days-to-cover on de minimis volume — negligible
Avg daily volume: ~25K ADRs/day (≈250K share-equivalents) — thin; CSE PHOS remains the liquidity venue
Float / shares out: 150.5M / 189.1M (~80%); placement stock unlocks Q4 2026
Warrant overhang: Cleared — only 2.625M remain, all insider-held; 2.46M exercised at C$1.25 (Apr 2026) for C$3.07M
Options + RSUs: 7.65M options + 1.975M RSUs, all held by staff/management/board (May 4, 2026)
Cash position: >C$30M, debt-free per company (post July raise + federal contribution)
Analyst coverage: Emerging Growth Research only named shop — Buy, C$4.94 (Aug 2026); no bank coverage

Conviction Analysis

Systematic Conviction Score: 44/100 (Low)

Analyst Alignment

30%

FCF Visibility

25%

Catalyst Clarity

20%

Valuation Safety

15%

Mgmt Quality

10%

Coverage is a single named micro-cap shop plus two anonymous TipRanks Buys — directionally aligned but institutionally unvalidated (50). FCF visibility is minimal: pre-revenue, ~C$29.7M TTM net loss, C$675M capex ahead, first FCF plausibly 2029–2030 (12). The catalyst calendar is unusually legible — feasibility end-2026/Q1-27, BAPE, FID end-2027, ECA conversions, post-Nasdaq discovery (75). Valuation looks cheap at ~0.26x PEA NAV but PEA-stage accuracy, guaranteed dilution and a +438% run compress the margin of safety (30). Management owns ~20%, buys in the open market and secured C$21.5M non-dilutive federal money, offset by a promotional news cadence and 156% share-count growth (62). Weighted score 44 → Low tier: a real story that has already been paid for a year in advance.

Risk & Ownership

Risk Assessment & Insider Signals

OOwnership & Insider Signals

CEO John Passalacqua — ~9.99% partially diluted: Per the July 3, 2026 early warning report, Passalacqua holds ~9.99% partially diluted; the drop below 10% (from ~18.8% in July 2024) came from placement dilution, not selling. He has bought ~2.87M shares in the open market since May 2023.
Total insider ownership ~20.4%: StockAnalysis (Aug 19, 2026): insiders hold 20.41% of 189.14M shares. Per the May 4, 2026 cap-table release, ALL outstanding warrants (2.625M), options (7.65M) and RSUs (1.975M) are held by current staff, management and board — no external overhang instruments remain.
Share count evolution — 73.8M → 189.1M in two years: 73.79M (Jul 2024) → 179.95M (May 4, 2026) → ~189.1M after the July 10, 2026 C$17.7M oversubscribed placement. ~C$80M raised since June 2022 across management-led, non-brokered placements — dilutive but broker-fee-light and insider-anchored. The EDGAR cover count (73.79M) behind the $120M market-cap display is badly stale.
Institutional presence ~11%, rising post-Nasdaq: Institutional ownership 10.98% — modest, typical for a CSE junior. The Aug 10, 2026 Nasdaq Global Market ADR uplisting (1 ADR = 10 shares) removes a key access barrier; no meaningful 13F base exists yet.
Float ~150.5M shares (~80% of outstanding): Effective tradeable float is smaller near-term: June/July 2026 placement shares (~8.85M+) carry four-month Canadian holds into Q4 2026, and insider blocks (~20%) are sticky.
Government of Canada as de facto strategic backer: C$16.7M non-repayable NRCan contribution (Mar 2026) within ~C$21.5M total federal contributions; company reports >C$30M cash and debt-free status post-raise. G7 CMRPA arrangements add allied-government sponsorship without equity dilution.

Risk Heatmap

Quantified Risk Assessment

Severity Risk Factor Prob. PT Impact

High Construction financing gap — C$675M capex vs ~US$305M real cap

PEA capex of C$675M (plus the Port Saguenay acid plant) is several times the company's equity value even on the corrected ~189M share count. G7-era EXIM/EIFO/Italian ECA letters of interest are non-binding; absent debt or strategic equity, dilution to production is severe. Share count already grew 73.8M (Jul 2024) → ~189.1M (Aug 2026), +156% in two years.

80% -30%

High Permitting/BAPE timeline slippage in Quebec

Targets: feasibility end-2026/Q1-27, permitting through 2027, FID end-2027. Quebec's BAPE review routinely adds 12–18 months for mining projects; Filon fast-track selection helps coordination but issues no permits. Any slip pushes 2029 first production and forces interim financings at unknown prices.

45% -25%

High China LFP/purified phosphoric acid dominance

China controls ~100% of LFP cathode output and ~75% of purified phosphoric acid capacity. Chinese producers sold below cost through 2023–2025; a renewed strategic price war could undercut any Western entrant before Bégin-Lamarche produces (~2029+). The premium ex-China thesis depends on tariff/policy support holding for years.

50% -35%

High Single-asset, PEA-stage execution risk

Essentially all value sits in one PEA-stage project plus an unbuilt downstream strategy. The disclosed offtake prepayment was US$530K from an unnamed purchaser, refundable if feasibility doesn't advance. PEA economics carry ±30–50% accuracy; feasibility studies routinely re-rate capex upward.

40% -30%

Medium Momentum reversal — RSI 69.7 after +438%, thin tape

Stock is 37% above its 50-DMA and 82% above its 200-DMA after a news-cadence-fueled run (federal money, G7 offtakes, Nasdaq uplisting). ADR volume ~25K/day is thin; June/July placement stock (C$2.00 pricing) becomes free-trading in Q4 2026, adding supply into any air pocket.

55% -20%

Medium Phosphate concentrate/merchant price exposure

PEA revenue assumes premium pricing for high-purity igneous apatite concentrate vs sedimentary rock. The 200kt/60kt offtakes establish volume but disclosed terms don't confirm binding floor prices; a fertilizer/PPA price downturn before FID would pressure both NPV and financing terms.

40% -15%

Recommendation

Summary

Rating

HOLD

Conviction

Low

Price Target

$1.8

Timeframe

12–18 mo

Upside

+11%

Position Size

≤1.5–2% (speculative)

Entry Strategy

Tranche 1 — 0.5%

$1.40–1.45

Starter only on a pullback to the June/July placement pricing zone (C$2.00 units ≈ US$1.45) — where insiders and new money just paid. Chasing at $1.62 with RSI 69.7 after a +438% run is paying for last year's catalysts.

Tranche 2 — 0.5–1%

$1.15–1.20

Add at the 50-DMA if the uptrend holds — this retest is likely during the Q4 2026 placement-stock unlock. Invalidate and stand aside on a weekly close below the 200-DMA ($0.89).

Tranche 3 — event-driven

Post-feasibility

The real position decision comes with the feasibility study (end-2026/Q1-27): confirmed ≥PEA economics plus an ECA commitment justifies paying up even above $2; a capex blowout or slip means the thesis re-prices regardless of chart level.

1-Year Price & Key Levels